This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Health Winners & Losers

Health indices were flat as few stocks peppered an overall dull hump day with a range of announcements.

Geron (GERN - Get Report) said Wednesday that it would receive a $4 million milestone payment as Merck (MRK - Get Report) filed an investigational new-drug application for a cancer vaccine candidate. Under a 2005 license agreement between the companies, Geron is eligible for development milestones and royalties on worldwide product sales of vaccines targeting the enzyme telomerase.

Geron shares nudged up 19 cents, or 2.9%, to $6.75. Merck was down 0.5% at $60.08.

Meanwhile another winner emerged after JMP analyst Charles Duncan upgraded Acadia Pharmaceuticals (ACAD - Get Report) to strong buy from market outperform. The analyst was recently impressed with midstage data on its schizophrenia drug candidate pimavanserin. The company's shares jumped $1.28, or 11.4%, to $12.48. The stock is a component of the Nasdaq biotechnology index, which was hovering just north of the flat line at 852.10.

On the regulatory side, Lannett (LCI - Get Report) received Food and Drug Administration-approval for the additional indication of the 30-mg dose of its phentermine hydrochloride capsules, the generic equivalent of Teva's (TEVA) Adipex, for short-term management of obesity. The company expects to begin marketing the product immediately. Lannett shares added 20 cents, or 6%, to $3.55.

Elsewhere, Neurocrine (NBIX) is awaiting the FDA's decision on sleep aid indiplon, which is designed to be used as needed to help a person fall back asleep once he or she wakes up in the middle of the night. The FDA rejected the extended-release form last year but granted conditional approval to the immediate-release formula if the company analyzed old data and conducted a test on how the drug was absorbed and excreted by the body and how it reacts with certain foods. Ahead of the FDA's decision, shares were down 18 cents, or 1.7%, to $10.20.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ACAD $38.36 0.00%
COO $181.75 0.00%
GERN $4.30 0.00%
LCI $67.40 0.00%
NBIX $43.37 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs